psiqi

INVESTOR OVERVIEW

Measured medicine starts here.

An acquisition-led platform for analytical science and future research capabilities.



Pre-acquisition / Colorado focus

THE INVESTMENT LOGIC

Acquire a sound laboratory. Earn the right to expand.

Start with an operating business, retain its scientific talent and customer relationships, and strengthen quality and service. Underwrite the acquisition on verified standalone economics. Fund later capabilities only when customer evidence and lawful scope justify them.

PROPOSED TARGET PROFILE

$500k–$3m

Annual revenue of a potential acquisition target. A screening range, not PSIQI revenue or a valuation.

Established analytical laboratory

Colorado focus, subject to suitability. Repeat customers; strong science and QA leadership; reliable records; manageable capital needs; HPLC/LC-MS capability where relevant.

Current stage: no acquisition, revenue, registration, accreditation, GMP capability or funding commitment has been verified for PSIQI. Capital needs and team appointments remain to be established.

A DISCIPLINED PATH

Progress needs proof.

1 Laboratory foundation	Validate a target shortlist, buyer demand, normalized earnings, ownership fit and key staff retention.
2 Specialized services	Price methods, stability and analytical work against customer needs, qualified methods and available capacity.
3 Research capabilities	Require a defined lawful scope, appropriate registrations, eligible customers and funded quality readiness.
4 Future API pathway	Compare specialist partnerships with owned capability. Treat GMP manufacture as a separate investment decision.

WHY REVISIT THE THESIS NOW

FDA finalized its psychedelic clinical-investigation guidance in July 2026. Compass reported completing its COMP360 NDA submission on November 9. These are relevant sector milestones; an NDA submission is not approval, and neither event establishes PSIQI demand or a supply shortage.

DILIGENCE THAT MATTERS

Customer concentration, staffing continuity, equipment and QA condition, capital requirements and licensing transitions. Colorado testing-independence rules may constrain common ownership. DEA registrations do not automatically transfer. Existing suppliers compete in this market.

Selected sources: FDA final guidance / Compass Nov. 9 release / Colorado testing rules / 21 CFR 1301.52

Discussion: info@psiqi.com • psiqi.com

Business thesis only; not an offer of securities. Imagery is AI-generated and does not depict a PSIQI facility. Full research context and proposed milestones accompany the project documentation.